$REGN

Eli Lilly eyes $2 trillion valuation from weight-loss drugs, Alzheimer's breakthroughs, and AI-powered R&D following recent market pullback.

Over 50 drugmakers advance 55+ hemophilia treatments as Novo Nordisk and competitors pursue gene therapies and next-gen factors.

Complement inhibitors market projected for strong growth through 2036, driven by rising disease prevalence and C5/C3-targeted drug approvals across multiple indications.

Oil surges 5-6% on Iran tensions; Treasury yields top 4.4%. Fed holds rates at 3.75% as tech stocks fall 1-2% on OpenAI revenue miss.

Intellia Therapeutics raises $180M via stock offering at $10.75/share to advance CRISPR gene-editing therapies, with lead underwriters Jefferies, Goldman Sachs, Citigroup.

Regeneron agrees with Trump Administration to lower drug prices via Medicaid benchmarking and free gene therapy access, receiving three years of tariff relief and regulatory certainty.

FDA approves $REGN's Otarmeni, first dual AAV gene therapy for genetic hearing loss, in record 61 days under priority voucher program. 80% of patients showed improved hearing.

Regeneron offers gene therapy Otarmeni free and Praluent at lower pricing in exchange for tariff relief and exemption from future pricing mandates.

Over 65 pharma companies advance 75+ COPD drugs, shifting from traditional bronchodilators to targeted biologics as AstraZeneca's tozorakimab validates new approaches.

Sanofi's Dupixent gains FDA approval for pediatric urticaria as Q1 earnings beat expectations with 30.8% drug growth at $12.31B sales.

FDA approves Dupixent for children ages 2-11 with uncontrolled chronic spontaneous urticaria, marking first biologic treatment for this pediatric population.

FDA approves Dupixent for children ages 2-11 with chronic spontaneous urticaria, marking first biologic treatment for this pediatric population.

Bispecific antibody market projected to reach $60 billion by 2031 from $16 billion in 2025, with 550+ clinical trials and 18 approved drugs driving sector transformation.

Over 100 pharmaceutical companies compete to develop 120+ NSCLC pipeline drugs, with 30+ in late-stage trials. Precision oncology advances drive innovation in biomarker-selected populations.

Generalized myasthenia gravis market valued at $5.9B in 2025, projected to grow 9.1% annually through 2036 as eight promising late-stage therapies advance.

US eosinophilic esophagitis market valued at $647M in 2025 projected to grow 13.2% annually through 2036, driven by novel drug classes and improved diagnostics.

Neomorph closes $100M Series B led by Deerfield Management to advance NEO-811, its molecular glue degrader for kidney cancer, and expand its pipeline.

Telix Pharma secures $2.14B partnership with Regeneron for solid tumor radiopharmaceuticals while reporting 11% quarterly revenue growth and FDA acceptance of brain cancer imaging application.

Sanofi and Regeneron win EU approval for Dupixent as first targeted therapy for chronic urticaria in children ages 2-11, expanding the blockbuster drug's market reach.

Dupixent gains European approval for treating moderate-to-severe chronic spontaneous urticaria in children ages 2-11, expanding the drug's pediatric portfolio.